Akorn (PRIVATE.AKRX)

Overall impact
C (54)

Commentary

Akorn is an average overall performer. With a 'C' rating of 54.0 for overall impact (50th percentile compared to all companies), Akorn ranks 29th out of 33 industry peers, behind Zoetis, Adamas Pharmaceuticals, Ironwood Pharmaceuticals and 25 others, and ahead of Catalent, Collegium Pharmaceutical, Viatris and 1 other. On top material causes for Akorn's industry (Pharmaceuticals & Biotech), Akorn performs well in Racial Justice and Civil Rights (90.2 score) and performs poorly in Accountable Institutions (24.8 score), Accountable Institutions (24.9), Child and Maternal Health (20.9) and 2 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.AKRX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
2,191
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Illinois, United States
Share classes
PRIVATE.AKRX
Description
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter (OTC) drug products, and animal health products in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. This segment's primary products include Atropine Sulfate Ophthalmic Solution; Clobetasol Propionate Cream And Ointment; Ephedrine Sulfate Injection; Lidocaine Ointment; Methylene Blue Injection; Myorisan soft gelatin capsules; Nembutal sodium solution; Phenylephrine Hydrochloride Ophthalmic Solution; and Zioptan tafluprost ophthalmic solution. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Material causes
Ethos considers the following causes material for Akorn, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.